JP2015178529A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015178529A5 JP2015178529A5 JP2015129772A JP2015129772A JP2015178529A5 JP 2015178529 A5 JP2015178529 A5 JP 2015178529A5 JP 2015129772 A JP2015129772 A JP 2015129772A JP 2015129772 A JP2015129772 A JP 2015129772A JP 2015178529 A5 JP2015178529 A5 JP 2015178529A5
- Authority
- JP
- Japan
- Prior art keywords
- hsv
- seq
- vaccine formulation
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 claims 65
- 238000009472 formulation Methods 0.000 claims 54
- 239000000203 mixture Substances 0.000 claims 54
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 51
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 48
- 229920001184 polypeptide Polymers 0.000 claims 35
- 102000004196 processed proteins & peptides Human genes 0.000 claims 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims 35
- 125000003275 alpha amino acid group Chemical group 0.000 claims 31
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 17
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 14
- 150000001413 amino acids Chemical class 0.000 claims 13
- 208000024891 symptom Diseases 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 11
- 230000002163 immunogen Effects 0.000 claims 11
- 125000000539 amino acid group Chemical group 0.000 claims 10
- 208000015181 infectious disease Diseases 0.000 claims 10
- 230000037430 deletion Effects 0.000 claims 9
- 238000012217 deletion Methods 0.000 claims 9
- 230000003902 lesion Effects 0.000 claims 8
- 239000003937 drug carrier Substances 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 230000007485 viral shedding Effects 0.000 claims 4
- 230000005867 T cell response Effects 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 206010019233 Headaches Diseases 0.000 claims 2
- 208000001688 Herpes Genitalis Diseases 0.000 claims 2
- 101150027427 ICP4 gene Proteins 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000037048 Prodromal Symptoms Diseases 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 201000004946 genital herpes Diseases 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 230000007794 irritation Effects 0.000 claims 2
- 230000007803 itching Effects 0.000 claims 2
- 206010025482 malaise Diseases 0.000 claims 2
- 230000036407 pain Effects 0.000 claims 2
- PIGTXFOGKFOFTO-FVFWYJKVSA-N (2S,3S,4S,5R,6R)-6-[[(3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-carboxy-4-formyl-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)C[C@@H](O)[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O PIGTXFOGKFOFTO-FVFWYJKVSA-N 0.000 claims 1
- 208000032420 Latent Infection Diseases 0.000 claims 1
- 210000000447 Th1 cell Anatomy 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 230000005875 antibody response Effects 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000036755 cellular response Effects 0.000 claims 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000014599 transmission of virus Effects 0.000 claims 1
- 230000007419 viral reactivation Effects 0.000 claims 1
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18078409P | 2009-05-22 | 2009-05-22 | |
| US61/180,784 | 2009-05-22 | ||
| US23562809P | 2009-08-20 | 2009-08-20 | |
| US61/235,628 | 2009-08-20 | ||
| US24062609P | 2009-09-08 | 2009-09-08 | |
| US24058709P | 2009-09-08 | 2009-09-08 | |
| US61/240,587 | 2009-09-08 | ||
| US61/240,626 | 2009-09-08 | ||
| US30591810P | 2010-02-18 | 2010-02-18 | |
| US61/305,918 | 2010-02-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012512087A Division JP5771605B2 (ja) | 2009-05-22 | 2010-05-24 | 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015178529A JP2015178529A (ja) | 2015-10-08 |
| JP2015178529A5 true JP2015178529A5 (https=) | 2016-06-09 |
| JP6096839B2 JP6096839B2 (ja) | 2017-03-15 |
Family
ID=43126545
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012512087A Expired - Fee Related JP5771605B2 (ja) | 2009-05-22 | 2010-05-24 | 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物および方法 |
| JP2015129772A Expired - Fee Related JP6096839B2 (ja) | 2009-05-22 | 2015-06-29 | 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012512087A Expired - Fee Related JP5771605B2 (ja) | 2009-05-22 | 2010-05-24 | 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物および方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8617564B2 (https=) |
| EP (3) | EP3756684A1 (https=) |
| JP (2) | JP5771605B2 (https=) |
| KR (1) | KR101746872B1 (https=) |
| CN (2) | CN106924728B (https=) |
| AU (1) | AU2010249330B2 (https=) |
| BR (1) | BRPI1012811A2 (https=) |
| CA (1) | CA2797937C (https=) |
| ES (1) | ES2732815T3 (https=) |
| IL (1) | IL216508A (https=) |
| MX (1) | MX2011012347A (https=) |
| MY (1) | MY159500A (https=) |
| NZ (1) | NZ597182A (https=) |
| RU (1) | RU2585961C9 (https=) |
| SG (1) | SG176207A1 (https=) |
| WO (2) | WO2010135749A1 (https=) |
| ZA (1) | ZA201109444B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3756684A1 (en) | 2009-05-22 | 2020-12-30 | Genocea Biosciences, Inc. | Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response |
| JP2013525271A (ja) | 2010-03-12 | 2013-06-20 | チルドレンズ メディカル センター コーポレーション | 免疫原およびそのスクリーニング方法 |
| JP6055776B2 (ja) * | 2010-11-24 | 2016-12-27 | ジェノセア バイオサイエンシーズ， インコーポレイテッド | 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法 |
| WO2012139099A2 (en) * | 2011-04-08 | 2012-10-11 | Duke University | Herpes simplex virus vaccine |
| EA027236B1 (ru) | 2011-04-08 | 2017-07-31 | Иммьюн Дизайн Корп. | Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа |
| AU2012340712B2 (en) * | 2011-11-23 | 2017-09-14 | Genocea Biosciences, Inc. | Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response |
| HRP20181102T1 (hr) | 2012-05-16 | 2018-09-07 | Immune Design Corp | Cjepiva za hsv-2 |
| WO2014052971A1 (en) * | 2012-09-30 | 2014-04-03 | The Regents Of The University Of Michigan | Immunogenic compositions comprising nanoemulsions |
| CN103074337B (zh) * | 2012-12-04 | 2014-07-09 | 昆明寰基生物芯片产业有限公司 | 一段单纯疱疹病毒dna序列及应用 |
| US11576958B2 (en) | 2013-02-07 | 2023-02-14 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
| WO2014164699A1 (en) * | 2013-03-11 | 2014-10-09 | The Regents Of The University Of California | Herpes virus vaccines and treatments |
| US10918712B2 (en) | 2014-03-03 | 2021-02-16 | Albert Einstein College Of Medicine | Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors |
| EP3943106A1 (en) | 2014-03-03 | 2022-01-26 | Albert Einstein College of Medicine | Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors |
| DK3411388T3 (da) | 2016-02-01 | 2021-12-13 | Simplexia Ab | Trunkeret glycoprotein g af herpes simplex virus 2 |
| RS60410B1 (sr) * | 2016-04-08 | 2020-07-31 | Krystal Biotech Inc | Kompozicije za upotrebu u metodama za tretman rana, poremećaja i bolesti kože |
| US10350288B2 (en) | 2016-09-28 | 2019-07-16 | Genocea Biosciences, Inc. | Methods and compositions for treating herpes |
| KR101962683B1 (ko) * | 2016-09-28 | 2019-03-27 | 주식회사 에스엘백시젠 | Hsv-2 감염 예방 및 치료용 dna 백신 |
| WO2018200613A1 (en) * | 2017-04-26 | 2018-11-01 | Merck Sharp & Dohme Corp. | Hsv antigenic peptides and hsv protein vaccines |
| AU2018316811B2 (en) * | 2017-08-17 | 2023-07-13 | The Trustees Of The University Of Pennsylvania | Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof |
| US11213582B2 (en) * | 2018-08-08 | 2022-01-04 | The Regents Of The University Of California | Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits |
| CN112969474A (zh) | 2018-09-12 | 2021-06-15 | 艾芬尼维克斯公司 | 多价肺炎球菌疫苗 |
| EP3921334A1 (en) | 2019-02-08 | 2021-12-15 | Krystal Biotech, Inc. | Compositions and methods for delivering cftr polypeptides |
| US20240108747A1 (en) | 2019-03-21 | 2024-04-04 | Lonza Sales Ag | Extracellular vesicle conjugates and uses thereof |
| BR112021018694A2 (pt) | 2019-03-21 | 2021-11-30 | Codiak Biosciences Inc | Vesículas extracelulares para distribuição de vacina |
| CN109943592B (zh) * | 2019-04-29 | 2020-11-17 | 华中农业大学 | 含猪伪狂犬病病毒gD蛋白基因的重组杆状病毒转移载体、重组杆状病毒及制备方法和应用 |
| CN110845583A (zh) * | 2019-11-18 | 2020-02-28 | 维塔恩(广州)医药有限公司 | 水痘带状疱疹病毒相关抗原短肽及其应用 |
| CN110724181A (zh) * | 2019-11-18 | 2020-01-24 | 维塔恩(广州)医药有限公司 | 单纯疱疹病毒相关抗原短肽及其应用 |
| CN110804088A (zh) * | 2019-11-18 | 2020-02-18 | 维塔恩(广州)医药有限公司 | 巨细胞病毒相关抗原短肽及其应用 |
| CN110746497A (zh) * | 2019-11-18 | 2020-02-04 | 维塔恩(广州)医药有限公司 | 肺炎衣原体相关抗原短肽及其应用 |
| BR112023020209A2 (pt) | 2021-04-02 | 2023-12-19 | Krystal Biotech Inc | Genoma do vírus do herpes recombinante, vírus do herpes, composição farmacêutica, uso do vírus do herpes ou da composição farmacêutica, método para expressar, realçar, aumentar, ampliar e/ou suplementar os níveis de um polipeptídeo imunomodulatório, método para prover alívio profilático, paliativo ou terapêutico, e, método para tratar câncer |
| MX2024002779A (es) | 2021-09-09 | 2024-06-11 | Affinivax Inc | Vacunas neumocócicas multivalentes. |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4818694A (en) * | 1982-07-20 | 1989-04-04 | American Cyanamid Company | Production of herpes simplex viral protein |
| NZ209308A (en) * | 1983-08-30 | 1991-08-27 | Genentech Inc | Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein |
| US7264817B1 (en) * | 1983-08-30 | 2007-09-04 | Genentech, Inc. | Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it |
| US5244792A (en) * | 1984-04-06 | 1993-09-14 | Chiron Corporation | Expression of recombinant glyoprotein B from herpes simplex virus |
| US5171568A (en) * | 1984-04-06 | 1992-12-15 | Chiron Corporation | Recombinant herpes simplex gb-gd vaccine |
| US5612041A (en) * | 1984-07-17 | 1997-03-18 | Chiron Corporation | Recombinant herpes simplex gD vaccine |
| US5149529A (en) * | 1988-04-08 | 1992-09-22 | Board Of Trustees Of Leland Chiron Corporation | Compositions and treatment for herpes simplex |
| EP0471778A1 (en) * | 1989-05-12 | 1992-02-26 | Ciba Corning Diagnostics Corp. | Herpes simplex virus type 2-glycoprotein g proteins and polypeptides |
| CA2088600C (en) * | 1990-08-02 | 1999-11-16 | Rae L. Burke | Herpes simplex virus vp16 vaccines |
| DK31991D0 (da) * | 1991-02-25 | 1991-02-25 | Carlbiotech Ltd As | Peptid og farmaceutisk praeparat indeholdende et saadant peptid |
| GB9105992D0 (en) * | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccine |
| US5955088A (en) | 1992-02-03 | 1999-09-21 | Cedars-Sinai Medical Center | Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins |
| US5679348A (en) | 1992-02-03 | 1997-10-21 | Cedars-Sinai Medical Center | Immunotherapy for recurrent HSV infections |
| US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| EP0708833A1 (en) | 1993-06-08 | 1996-05-01 | Abbott Laboratories | Herpes simplex virus type-2 protease |
| EP0714399A4 (en) | 1993-08-20 | 1999-01-27 | Smithkline Beecham Corp | HSV-2 UL26 GEN, ENVELOPE PROTEINS, IMMUNOASSAYS AND PROTEAS INHIBITORS |
| GB9325496D0 (en) * | 1993-12-14 | 1994-02-16 | Smithkline Beecham Biolog | Vaccines |
| US7094767B2 (en) * | 1994-07-22 | 2006-08-22 | Merck & Co., Inc. | Polynucleotide herpes virus vaccine |
| US6156319A (en) * | 1994-07-25 | 2000-12-05 | The Trustees Of The University Of Pennsylvania | Soluble herpesvirus glycoprotein complex vaccine |
| US5807557A (en) | 1994-07-25 | 1998-09-15 | The Trustees Of The University Of Pennsylvania | Soluble herpesvirus glycoprotein complex |
| AUPM873294A0 (en) * | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| US5962428A (en) * | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| WO1996032962A1 (en) * | 1995-04-21 | 1996-10-24 | The University Of New Mexico | Immunoassay for herpes simplex virus |
| US5654174A (en) * | 1995-07-07 | 1997-08-05 | Competitive Technologies, Inc. | Herpes simplex virus glycoprotein D variants |
| US5876923A (en) | 1996-07-26 | 1999-03-02 | Arch Development Corporation | Herpes simplex virus ICP4 as an inhibitor of apoptosis |
| KR100564268B1 (ko) * | 1996-10-23 | 2006-03-27 | 와이어쓰 | 백신 |
| CN1324139C (zh) * | 1996-10-23 | 2007-07-04 | 惠氏 | 疫苗 |
| CA2270282A1 (en) | 1996-11-04 | 1998-05-14 | Smithkline Beecham Corporation | Novel coding sequences from herpes simplex virus type-2 |
| US6218103B1 (en) * | 1997-04-16 | 2001-04-17 | Arch Development Corporation | Herpes simplex virus US3 and ICP4 as inhibitors of apoptosis |
| EP0984790A1 (en) | 1997-06-02 | 2000-03-15 | Chiron Corporation | Herpes simplex virus vp22 vaccines and methods of use |
| US6015832A (en) | 1997-12-31 | 2000-01-18 | The Regents Of The University Of Michigan | Methods of inactivating bacteria including bacterial spores |
| US6054131A (en) * | 1998-01-16 | 2000-04-25 | University Of Maryland Baltimore | Vaccine composition for herpes simplex virus and method of using |
| NZ506602A (en) * | 1998-03-09 | 2003-02-28 | Smithkline Beecham Biolog S | Combined vaccine compositions against hepatitis B virus and herpes simplex virus and possibly also epstein bar virus, hepatitis A & C viruses, human papilloma virus, varicella zoster virus, human cytomegalovirus, and toxoplasma gondii |
| US6248558B1 (en) | 1998-03-31 | 2001-06-19 | Vanderbilt University | Sequence and method for genetic engineering of proteins with cell membrane translocating activity |
| US6375952B1 (en) * | 1998-08-07 | 2002-04-23 | University Of Washington | Immunological herpes simplex virus antigens and methods for use thereof |
| US6692752B1 (en) * | 1999-09-08 | 2004-02-17 | Smithkline Beecham Biologicals S.A. | Methods of treating human females susceptible to HSV infection |
| US6635676B2 (en) | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US6506803B1 (en) | 1999-04-28 | 2003-01-14 | Regents Of The University Of Michigan | Methods of preventing and treating microbial infections |
| US6559189B2 (en) | 1999-04-28 | 2003-05-06 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| CA2375320C (en) * | 1999-06-10 | 2013-02-19 | Merial | Dna vaccines for pets or for animals used in sports |
| GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| EP1222281B1 (en) * | 1999-09-30 | 2006-11-15 | University of Washington | Immunoligically significant herpes simplex virus antigens |
| US7196066B1 (en) * | 1999-11-03 | 2007-03-27 | Powderject Vaccines, Inc. | DNA-vaccines based on constructs derived from the genomes of human and animal pathogens |
| ES2258987T3 (es) * | 1999-12-17 | 2006-09-16 | Wyeth Holdings Corporation | Vacuna para reforzar las respuestas inmunitarias al virus del herpes simple. |
| FR2804028B1 (fr) * | 2000-01-21 | 2004-06-04 | Merial Sas | Vaccins adn ameliores pour animaux de rente |
| US7078388B2 (en) | 2000-01-21 | 2006-07-18 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
| US7157437B2 (en) * | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
| US6821519B2 (en) * | 2000-06-29 | 2004-11-23 | Corixa Corporation | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| AU2001273128C1 (en) | 2000-06-29 | 2006-09-21 | Corixa Corporation | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| US20030165819A1 (en) * | 2000-06-29 | 2003-09-04 | Corixa Corporation | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| US6682892B2 (en) * | 2000-07-13 | 2004-01-27 | Pharmacia & Upjohn Company | Method for treating herpes viruses |
| US7569218B2 (en) * | 2000-07-27 | 2009-08-04 | The Trustees Of The University Of Pennsylvania | Compositions for and methods of using herpes simplex virus glycoprotein D to suppress immune responses |
| EP1178111A1 (en) | 2000-08-03 | 2002-02-06 | Lohmann Animal Health GmbH & Co. KG | Vaccination against host cell-associated herpesviruses |
| US20040220076A1 (en) * | 2000-11-16 | 2004-11-04 | Laure Aurelian | Prevention of recurrent viral disease |
| US6867000B2 (en) * | 2000-12-07 | 2005-03-15 | Wyeth Holdings Corporation | Method of enhancing immune responses to herpes |
| JP2006512401A (ja) | 2001-06-05 | 2006-04-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ナノエマルジョンワクチン |
| ATE488249T1 (de) * | 2001-07-31 | 2010-12-15 | Univ Washington | Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung |
| WO2003020108A2 (en) | 2001-09-04 | 2003-03-13 | Corixa Corporation | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| US20080299140A1 (en) * | 2002-05-24 | 2008-12-04 | The Regents Of The University Of California, | Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition |
| US20030219448A1 (en) * | 2002-05-24 | 2003-11-27 | Cedars-Sinai Medical Center | Peptide epitope-based vaccine for treating herpes simplex virus infections and related diseases |
| DK1523582T3 (da) * | 2002-07-18 | 2009-03-02 | Univ Washington | Hurtig, effektiv rensning af HSV-specifikke T-lymfocytter samt HSV-antigener identificeret derved |
| US7267940B2 (en) * | 2003-03-04 | 2007-09-11 | Bio-Rad Laboratories, Inc. | HSV-2 type-specific immunoassays using glycoprotein G2 peptides |
| CA2538794C (en) * | 2003-09-12 | 2016-04-19 | Antigenics, Inc. | Vaccine for treatment and prevention of herpes simplex virus infection |
| GB0321615D0 (en) * | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| US20120027841A1 (en) | 2004-01-07 | 2012-02-02 | Biomedical Research Models, Inc. | Novel mucosal vaccination approach for herpes simplex virus type-2 |
| AU2006338570B2 (en) * | 2005-11-18 | 2013-07-11 | The Ohio State University Research Foundation | Viral gene products and methods for vaccination to prevent viral associated diseases |
| CA2645507A1 (en) | 2006-03-10 | 2007-09-20 | The Regents Of The University Of California | Vaccine for viruses that cause persistent or latent infections |
| CA2658484A1 (en) * | 2006-07-20 | 2008-01-24 | Vical Incorporated | Compositions and methods for vaccinating against hsv-2 |
| WO2008027394A2 (en) | 2006-08-28 | 2008-03-06 | The Wistar Institute Of Anatomy And Biology | Constructs for enhancing immune responses |
| WO2008030560A2 (en) * | 2006-09-08 | 2008-03-13 | The Trustees Of The University Of Pennsyvania | Hsv-1 and hsv-2 vaccines and methods of use thereof |
| US9297803B2 (en) | 2006-11-01 | 2016-03-29 | Immport Therapeutics, Inc. | Compositions and methods for immunodominant antigens |
| US8057804B2 (en) * | 2006-12-28 | 2011-11-15 | The Trustees Of The University Of Pennsylvania | Herpes simplex virus combined subunit vaccines and methods of use thereof |
| US9284355B2 (en) * | 2006-12-28 | 2016-03-15 | The Trustees Of The University Of Pennsylvania | Herpes simplex virus combined subunit vaccines and methods of use thereof |
| WO2009006618A2 (en) | 2007-07-05 | 2009-01-08 | University Of Kansas | Herpes simplex virus mutant icp0 protein |
| US20130273088A1 (en) | 2007-07-06 | 2013-10-17 | Anthony Lawrence Cunningham | Epitopes of herpes simplex virus |
| EP2293814A4 (en) * | 2008-05-23 | 2013-02-13 | Univ Michigan | NANOEMULSION AGENTS |
| SE532551C2 (sv) | 2008-06-30 | 2010-02-16 | Senseair Ab | Ett för spektralanalys anpassat arrangemang |
| AU2009266924B2 (en) | 2008-07-01 | 2015-12-10 | Genocea Biosciences, Inc. | Antigen screening system |
| JP2012512257A (ja) | 2008-12-17 | 2012-05-31 | ジェノセア バイオサイエンシーズ， インコーポレイテッド | クラミジア抗原およびその使用 |
| US8460674B2 (en) * | 2009-02-07 | 2013-06-11 | University Of Washington | HSV-1 epitopes and methods for using same |
| CA2754592A1 (en) | 2009-03-09 | 2010-09-16 | William Henry | Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions |
| EP3756684A1 (en) | 2009-05-22 | 2020-12-30 | Genocea Biosciences, Inc. | Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response |
| WO2011106607A2 (en) | 2010-02-26 | 2011-09-01 | Juvaris Biotherapeutics, Inc. | Subunit vaccines for herpes viruses and methods of use |
| WO2012054755A1 (en) | 2010-10-20 | 2012-04-26 | Genocea Biosciences, Inc. | Chlamydia antigens and uses thereof |
| JP6055776B2 (ja) | 2010-11-24 | 2016-12-27 | ジェノセア バイオサイエンシーズ， インコーポレイテッド | 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法 |
| AU2012340712B2 (en) | 2011-11-23 | 2017-09-14 | Genocea Biosciences, Inc. | Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response |
| US10350288B2 (en) | 2016-09-28 | 2019-07-16 | Genocea Biosciences, Inc. | Methods and compositions for treating herpes |
-
2010
- 2010-05-24 EP EP20184815.7A patent/EP3756684A1/en not_active Withdrawn
- 2010-05-24 EP EP19172066.3A patent/EP3590533A1/en not_active Withdrawn
- 2010-05-24 MY MYPI2011005631A patent/MY159500A/en unknown
- 2010-05-24 BR BRPI1012811A patent/BRPI1012811A2/pt not_active IP Right Cessation
- 2010-05-24 KR KR1020117030122A patent/KR101746872B1/ko not_active Expired - Fee Related
- 2010-05-24 MX MX2011012347A patent/MX2011012347A/es active IP Right Grant
- 2010-05-24 ES ES10778532T patent/ES2732815T3/es active Active
- 2010-05-24 AU AU2010249330A patent/AU2010249330B2/en not_active Ceased
- 2010-05-24 CN CN201611104488.8A patent/CN106924728B/zh not_active Expired - Fee Related
- 2010-05-24 SG SG2011086535A patent/SG176207A1/en unknown
- 2010-05-24 CA CA2797937A patent/CA2797937C/en not_active Expired - Fee Related
- 2010-05-24 RU RU2011147153/15A patent/RU2585961C9/ru active
- 2010-05-24 JP JP2012512087A patent/JP5771605B2/ja not_active Expired - Fee Related
- 2010-05-24 WO PCT/US2010/036000 patent/WO2010135749A1/en not_active Ceased
- 2010-05-24 NZ NZ59718210A patent/NZ597182A/en not_active IP Right Cessation
- 2010-05-24 WO PCT/US2010/035998 patent/WO2010135747A1/en not_active Ceased
- 2010-05-24 CN CN201080033258.1A patent/CN102458463B/zh not_active Expired - Fee Related
- 2010-05-24 EP EP10778532.1A patent/EP2432504B1/en not_active Not-in-force
- 2010-05-24 US US12/786,425 patent/US8617564B2/en active Active
-
2011
- 2011-11-21 IL IL216508A patent/IL216508A/en active IP Right Grant
- 2011-12-21 ZA ZA2011/09444A patent/ZA201109444B/en unknown
-
2013
- 2013-11-12 US US14/077,676 patent/US9895436B2/en active Active
-
2015
- 2015-06-29 JP JP2015129772A patent/JP6096839B2/ja not_active Expired - Fee Related
-
2018
- 2018-01-03 US US15/860,742 patent/US10653771B2/en active Active - Reinstated
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015178529A5 (https=) | ||
| JP2012527486A5 (https=) | ||
| Benage et al. | Vaccine-associated uveitis | |
| Price et al. | Latent infection of sensory ganglia with herpes simplex virus: efficacy of immunization | |
| Odegard et al. | A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs | |
| Roth et al. | HSV-2 vaccine: current state and insights into development of a vaccine that targets genital mucosal protection | |
| RU2011147153A (ru) | Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа | |
| US20230084300A1 (en) | Prevention and treatment of infections including those caused by coronavirus | |
| JP2017158561A5 (https=) | ||
| JP2014506562A5 (ja) | 治療的免疫応答及び予防的免疫応答の両方を誘発するポリペプチド（複数可）保持ＣｙａＡ及びその使用 | |
| Cho et al. | Protective effects of red ginseng extract against vaginal herpes simplex virus infection | |
| Zhang et al. | A herpes simplex virus 2 (HSV-2) glycoprotein D-expressing nonreplicating dominant-negative HSV-2 virus vaccine is superior to a gD2 subunit vaccine against HSV-2 genital infection in guinea pigs | |
| Maugh | Chemotherapy: Antiviral agents come of age | |
| Wannigama et al. | NOD2-dependent BCG-induced trained immunity: A way to regulate innate responses to SARS-CoV2? | |
| JP7145863B2 (ja) | 改変型ＨＳＶ ｇＢタンパク質及びこれを含むＨＳＶワクチン | |
| Lin et al. | Water extract of Pueraria lobata Ohwi has anti-viral activity against human respiratory syncytial virus in human respiratory tract cell lines | |
| JP2014534262A5 (https=) | ||
| GB2607262A (en) | Prevention and treatment of infections including those caused by coronavirus | |
| Mori et al. | HF10, an attenuated herpes simplex virus (HSV) type 1 clone, lacks neuroinvasiveness and protects mice against lethal challenge with HSV types 1 and 2 | |
| Hua et al. | DNA vaccine encoding central conserved region of G protein induces Th1 predominant immune response and protection from RSV infection in mice | |
| CN113185586B (zh) | SARS-CoV-2编码蛋白来源的T细胞表位多肽及其应用 | |
| CN106317216A (zh) | 一种促进h9n2禽流感疫苗的活性肽及应用 | |
| Cho et al. | Design and immunogenicity of a quadrivalent mRNA vaccine targeting HSV-2 with comparative evaluation of co-formulated and admixed formulations | |
| Wan et al. | Comparison of effects of multiple adjuvants and immunization routes on the immunogenicity and protection of HSV-2 gD subunit vaccine | |
| WO2021238982A1 (zh) | 包含聚核苷酸的药物组合物及其用于预防或治疗covid-19的用途 |